Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €117.04 EUR
Change Today +1.28 / 1.10%
Volume 10.0
WMD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (WMD) Snapshot

Open
€116.20
Previous Close
€115.76
Day High
€119.13
Day Low
€115.80
52 Week High
04/14/15 - €129.23
52 Week Low
05/27/14 - €49.83
Market Cap
9.2B
Average Volume 10 Days
29.8
EPS TTM
--
Shares Outstanding
78.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (WMD)

medivation inc (WMD) Related Businessweek News

View More BusinessWeek News

medivation inc (WMD) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company’s prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.

485 Employees
Last Reported Date: 02/25/15

medivation inc (WMD) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $787.5K
Chief Financial Officer
Total Annual Compensation: $465.3K
Chief Medical Officer
Total Annual Compensation: $500.0K
Chief Commercial Officer
Total Annual Compensation: $179.7K
General Counsel and Corporate Secretary
Total Annual Compensation: $445.0K
Compensation as of Fiscal Year 2014.

medivation inc (WMD) Key Developments

Medivation, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year Ended December 31, 2015

Medivation, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $129,188,000, income from operations of $573,000, net loss before income tax benefit of $4,898,000, net loss of $3,118,000 or $0.04 per diluted share against collaboration revenue of $87,189,000, loss from operations of $8,465,000, net loss before income tax benefit of $13,274,000, net loss of $13,665,000 or $0.0.18 per diluted share a year ago. Non-GAAP collaboration revenue was $127,777,000 compared with $67,956,000 a year ago. Non-GAAP net income was $12,407,000 compared with loss of $4,056,000 a year ago. Non-GAAP diluted net income was $0.17 compared with loss per share were $0.05 a year ago. Total non-GAAP adjustments after tax was $16,525,000 compared with $9,609,000 a year ago. For the full year ending December 31, 2015. The company expects Net Sales of XTANDI of $1.050 to $1.125 billion. Non-GAAP Collaboration Revenue of $600 to $650 million. Non-GAAP Interest Expense of $5 million. Non-GAAP Tax Rate of 36-37%.

Medivation, Inc. to Report Q1, 2015 Results on May 07, 2015

Medivation, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015

Medivation, Inc., Q1 2015 Earnings Call, May 07, 2015

Medivation, Inc., Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WMD:GR €117.04 EUR +1.28

WMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.07 USD +0.23
Insys Therapeutics Inc $59.31 USD +2.08
Pfizer Ltd/India 2,225 INR +9.70
Sanofi India Ltd 3,286 INR +15.45
Seattle Genetics Inc $43.23 USD -0.53
View Industry Companies
 

Industry Analysis

WMD

Industry Average

Valuation WMD Industry Range
Price/Earnings 38.4x
Price/Sales 13.4x
Price/Book 21.5x
Price/Cash Flow 35.3x
TEV/Sales 12.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.